SmartAmp method can rapidly detect SARS-CoV-2 in dead bodies.


Journal

Forensic science international
ISSN: 1872-6283
Titre abrégé: Forensic Sci Int
Pays: Ireland
ID NLM: 7902034

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 19 10 2021
accepted: 21 12 2021
pubmed: 10 1 2022
medline: 28 1 2022
entrez: 9 1 2022
Statut: ppublish

Résumé

Rapid and accurate detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in dead bodies is essential to prevent infection among those working with dead bodies. This study focused on the Smart Amplification (SmartAmp) method, which has a short examination time (approximately an hour), is simple to perform, and demonstrates high specificity and sensitivity. This method has already been used for clinical specimens; however, its effectiveness in dead bodies has not been reported. This study examined the SmartAmp method using 11 autopsies or postmortem needle biopsies performed from January to May, 2021 (of these, five cases tested positive for SARS-CoV-2 by quantitative real-time polymerase chain reaction (qRT-PCR) and six cases tested negative). Swab samples were collected from the nasopharynx, oropharynx, or anus and the SmartAmp and qRT-PCR results were compared. For the nasopharynx and oropharynx samples, the same results were obtained for both methods in all cases; however, for the anal swabs, there was one case that was positive according to qRT-PCR but negative according to the SmartAmp method. The SmartAmp method may therefore be less sensitive than qRT-PCR and results may differ in specimens with a low viral load, such as anal swabs. However, in the nasopharynx and oropharynx specimens, which are normally used for testing, the results were the same using each method, suggesting that the SmartAmp method is useful in dead bodies. In the future, the SmartAmp method may be applied not only during autopsies, but also in various situations where dead bodies are handled.

Identifiants

pubmed: 34999365
pii: S0379-0738(21)00488-6
doi: 10.1016/j.forsciint.2021.111168
pmc: PMC8701773
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111168

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interests The authors declare no conflicts of interest associated with this manuscript.

Références

Nat Methods. 2007 Mar;4(3):257-62
pubmed: 17322893
Trends Biotechnol. 2011 May;29(5):240-50
pubmed: 21377748
Nucleosides Nucleotides Nucleic Acids. 2008 Mar;27(3):224-43
pubmed: 18260008
Angew Chem Int Ed Engl. 2009;48(35):6480-4
pubmed: 19637175
JMA J. 2021 Apr 15;4(2):67-75
pubmed: 33997438
PLoS One. 2012;7(1):e30236
pubmed: 22295077
Methods Mol Biol. 2009;578:437-51
pubmed: 19768611
Pharmacogenomics. 2009 Jul;10(7):1187-97
pubmed: 19604094
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33327991
J Infect Chemother. 2022 Jan;28(1):120-123
pubmed: 34580006
Hum Mutat. 2010 Feb;31(2):208-17
pubmed: 20052755
Cell Mol Life Sci. 2009 Oct;66(20):3325-36
pubmed: 19629390

Auteurs

Sayaka Nagasawa (S)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan. Electronic address: nagasawa.s@chiba-u.jp.

Aika Mori (A)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan.

Yuichiro Hirata (Y)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan.

Ayumi Motomura (A)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan; Department of Forensic Medicine, School of Medicine, International University of Health and Welfare, Kozunomori 4-3, Narita city, Chiba 286-8686, Japan.

Namiko Ishii (N)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan; Department of Forensic Medicine, School of Medicine, International University of Health and Welfare, Kozunomori 4-3, Narita city, Chiba 286-8686, Japan.

Keisuke Okaba (K)

Department of Forensic Medicine, School of Medicine, International University of Health and Welfare, Kozunomori 4-3, Narita city, Chiba 286-8686, Japan.

Kie Horioka (K)

Department of Forensic Medicine, School of Medicine, International University of Health and Welfare, Kozunomori 4-3, Narita city, Chiba 286-8686, Japan.

Yohsuke Makino (Y)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan; Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Makoto Nakajima (M)

Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Suguru Torimitsu (S)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan; Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Rutsuko Yamaguchi (R)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan; Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Go Inokuchi (G)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan; Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Fumiko Chiba (F)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan; Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Yumi Hoshioka (Y)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan.

Naoki Saito (N)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan.

Maiko Yoshida (M)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan.

Daisuke Yajima (D)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan; Department of Forensic Medicine, School of Medicine, International University of Health and Welfare, Kozunomori 4-3, Narita city, Chiba 286-8686, Japan.

Shinji Akitomi (S)

Department of Medical Crisis Management, Medical Corporation Ioukai, Higasisayamagaoka 5-2753, Tokorozawa City, Saitama 330-0854, Japan; Japan Medical Association Research Institute, Komagome 2-28-16, Bunkyo-ku, Tokyo 113-8621, Japan.

Hirotaro Iwase (H)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan; Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

Hisako Saitoh (H)

Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1,Chuo-ku, Chiba city, Chiba, 260-8670, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH